Little is known about the molecular mechanisms that determine the entry into the lymph node and intranodal positioning of lymph-derived cells. By injecting cells directly into afferent lymph vessels ...

The autonomic nervous system innervates all body organs, including the cardiovascular system. Smooth muscle in arteries, arterioles, and veins and pericytes in capillaries receive autonomic ...

Afferent Also Appoints Kathleen Sereda Glaub to the Company's Board of Directors SAN MATEO, Calif.--(BUSINESS WIRE)--Afferent Pharmaceuticals today announced that Michael M. Kitt, M.D., has been named ...

- Neuroscience Industry Veteran to Lead Development of Chronic Pain Treatments; Technology Targets Novel Biological Pathway - PALO ALTO, Calif.--(BUSINESS WIRE)--Afferent Pharmaceuticals, a ...

Merck & Co has agreed to buy Afferent Pharmaceuticals, and its lead respiratory drug, in a deal worth up to $1.25 billion. The acquisition comes at a time when Merck’s revenues are beginning to ...

Please provide your email address to receive an email when new articles are posted on . Lee, the chair of the Department of Ophthalmology at Houston Methodist Hospital, said a relative afferent ...

KENILWORTH, N.J. & SAN MATEO, Calif.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, and Afferent Pharmaceuticals announced today that the two companies have ...

New company raised $23 million in a Series A financing round. A new company Afferent Pharmaceuticals has been founded with $23 million in Series A funding to develop new treatments for chronic pain ...

Merck & Co. Inc. MRK announced its intention to acquire privately held biotech company Afferent Pharmaceuticals in a deal which could see the company paying up to $1.25 billion. Deal to Add Chronic ...

Merck & Co. (MRK) might be slipping in Friday’s session, but the company is definitely making waves in its industry with its most recent acquisition agreement. Merck and Afferent Pharmaceuticals ...

Investors are backing several biotech firms created to advance molecules discarded by larger drug companies. Validating the strategy, Merck & Co. has agreed to pay $500 million to acquire one of them: ...